Locally advanced esophageal cancer: What becomes of 5-year survivors?

Galal Ghaly, MD,^a Mohamed Kamel, MD,^a Abu Nasar, MS,^a Subroto Paul, MD,^a Paul C. Lee, MD,^a Jeffrey L. Port, MD,^a Paul J. Christos, DrPH,^b Brendon M. Stiles, MD,^a and Nasser K. Altorki, MD^a

ABSTRACT

Objective: To determine the long-term outcomes of patients with locally advanced esophageal cancer (LAEC) who underwent esophagectomy and survived at least 5 years, and the predictors of disease-free survival (DFS) beyond 5 years.

Methods: This was a retrospective review of a prospective database to identify patients with clinical stage T2N0M0 or higher LAEC. Medical records were reviewed to obtain demographic, clinical, and pathological characteristics, as well as data on recurrence and survival. Multivariable analysis of predictors of DFS beyond 5 years was performed using a Cox regression model.

Results: Between 1988 and 2009, 355 of 500 patients underwent esophagectomy for cT2N0M0 or higher disease. Of these 355 patients, 126 were alive and disease-free at the 5-year follow-up, for an actuarial 5-year DFS of 33%. Recurrent esophageal cancer developed in 8 patients after 5 years. Among the 126 surviving patients, the actuarial overall survival was 94% at 7 years and 80% at 10 years. On multivariable analysis, the sole significant predictor of DFS after the 5-year time point was non-en bloc resection at the original operation ($P = .006$). Pulmonary-related deaths accounted for 10 out of 22 noncancer deaths. A second primary cancer developed in 23 of the 126 surviving patients.

Conclusions: Prolonged survival can be obtained in one-third of patients with LAEC. An en bloc resection at the original operation is the most significant predictor of prolonged survival. Survivors experience a high rate of second primary cancer and an apparently high rate of deaths from pulmonary disease. Careful follow-up is necessary for these patients, even after the 5-year mark. (*J Thorac Cardiovasc Surg* 2016;151:726-32)

Overall survival for disease-free patients after 5 years of follow-up.

Central Message

In LAEC patients who survived at least 5 years after esophagectomy, actuarial overall survival at 10 years and 15 years is 80% and 59%, respectively. Although recurrent EC is uncommon, patients remain at risk for another primary cancers and pulmonary morbidities.

Perspective

Among 5-year survivors, non-en bloc resection was the sole significant predictor of disease-free survival. Recurrent esophageal cancer, another primary cancers, and pulmonary diseases were the most common causes of death beyond 5 years postesophagectomy. Careful follow-up is mandatory for patients with locally advanced esophageal cancer even after 5 years of follow-up.

See Editorial Commentary page 733.

See Editorial page 631.

From the ^aDivision of Thoracic Surgery, Department of Cardiothoracic Surgery and ^bDivision of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY.

P.J.C. was partially supported by the Clinical and Translational Science Center at Weill Cornell Medical College (Grant UL1-TR000457-06).

Read at the 95th Annual Meeting of The American Association for Thoracic Surgery, Seattle, Washington, April 25-29, 2015.

Received for publication April 22, 2015; revisions received Oct 14, 2015; accepted for publication Oct 18, 2015; available ahead of print Dec 1, 2015.

Address for reprints: Nasser K. Altorki, MD, Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Suite M404, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021 (E-mail: nkaltorki@med.cornell.edu).

0022-5223/\$36.00

Copyright © 2016 by The American Association for Thoracic Surgery

<http://dx.doi.org/10.1016/j.jtcvs.2015.10.096>

Despite advances in surgical techniques and neoadjuvant treatment strategies, locally advanced esophageal cancer (LAEC) remains a virulent malignancy associated with poor survival.^{1,2} Advances in surgical techniques,

Scanning this QR code will take you to the article title page. To view the AATS 2015 Webcast, see the URL at the end of the article.

Abbreviations and Acronyms

CCI	=	Charlson Comorbidity Index
CI	=	confidence interval
CT	=	computed tomography
DFS	=	disease-free survival
LAEC	=	locally advanced esophageal cancer
OS	=	overall survival
PET	=	positron emission tomography

perioperative care, and preoperative treatment strategies have improved outcomes somewhat; however, long-term survival beyond 5 years is considered uncommon. There is little published information on the outcome of patients with LAEC treated by esophagectomy with or without induction therapy beyond the 5-year mark, and whether these patients are truly cured remains unclear. The objective of the present study was to determine the outcomes of patients with LAEC clinically staged as T2N0M0 or higher who had survived at least 5 years after esophagectomy and were without disease at that time point.

PATIENTS AND METHODS**Study Design**

We conducted a retrospective review of a prospectively assembled thoracic surgery database. The Institutional Review Board of Weill Cornell Medical College and the New York–Presbyterian Hospital approved the database and the study design. Patient consent was waived. Patients were considered eligible for this review who had locally advanced carcinoma of the esophagus or gastroesophageal junction (Siewert type I or II) clinically staged as cT2N0M0 or higher and were treated by esophagectomy, with or without preoperative induction therapy, between January 1988 and September 2009. Patients undergoing esophagectomy after September 2009 were excluded, to obtain a minimum of 5 years of follow-up. Patients with clinical T1 disease were also excluded, because they were considered to have early-stage disease with a favorable long-term outcome.

A total of 355 patients met the selection criteria, of whom 126 patients were alive and disease-free at the 5-year time point. The hospital records of these 126 patients were reviewed for demographic and clinical characteristics, including age, sex, clinical stage, and use of neoadjuvant therapy. Performance status of all patients was graded according to Eastern Cooperative Oncology Group guidelines, and comorbidities were graded using the Charlson Comorbidity Index (CCI).³ Records were also reviewed for perioperative and pathological data, including surgical approach, extent of resection, fields of lymph nodes resected, pathological stage, histological cell type, and completeness of resection (R status).

Preoperative Evaluation

All patients were evaluated by history, physical examination, upper gastrointestinal endoscopy with biopsy and computed tomography (CT) of the chest and upper abdomen. Endoscopic ultrasonography and positron emission tomography (PET) were routinely obtained preoperatively only in the latter half of the cohort, from 1999 to 2009. Pulmonary function tests

were routinely obtained, and cardiac stress testing was done if risk factors were present. Patients were considered for surgical resection if preoperative evaluation revealed no evidence of distant visceral metastases or clear evidence of direct tumor invasion of the airway or major vascular structures. The presence of extensive nodal disease was not considered a contraindication to resection unless it clearly extended beyond the proposed fields of dissection.

Neoadjuvant Therapy

The majority of patients received neoadjuvant chemotherapy alone. Neoadjuvant chemotherapy included 2 to 4 cycles of a platinum-based regimen with either a taxane or epirubicin and capecitabine. Preoperative chemoradiotherapy was provided using either cisplatin/5-fluorouracil or, more commonly, carboplatin/paclitaxel delivered concurrently with radiotherapy. Esophagectomy was performed at 3 to 6 weeks after the conclusion of preoperative therapy.

Surgical Treatment

Esophagectomy was performed with either a transthoracic en bloc approach or a transhiatal approach. En bloc esophagectomy with 2- or 3-field lymphadenectomy was performed in medically fit patients aged <80 years. The basic technique of en bloc esophagectomy has been described previously.⁴ Alternatively, resection was done by either a non-en bloc conventional (Ivor-Lewis) transthoracic approach or a transhiatal approach. Regardless of surgical approach, upper abdominal and retroperitoneal node dissection was performed in all patients. Reconstruction with a greater curvature gastric tube was done in most of cases. Pathological staging was done according to the TNM classification of the seventh edition of the American Joint Committee for Cancer staging manual.⁵

Follow-up

After hospital discharge, patients were seen at 3-month intervals for the first 12 months, then every 6 months up to year 3, and annually thereafter. Patients from distant geographic locations were followed by contacting their treating physician and/or by direct telephone contact. CT scans of the chest and upper abdomen were done postoperatively every 6 months for 3 years and annually thereafter. Other studies, such as endoscopy and PET scanning, were done only if clinically indicated. All data were collected, entered into a prospective database, and updated at regular intervals until the patient's last follow-up or death.

Recurrence

Local recurrence was defined as recurrence within the wall or the lumen at or close to the anastomotic site. Regional recurrence was defined as nodal recurrence at any site within the operative field. Distant recurrence was defined as any tumor recurrence in nodal basins outside the field of surgical dissection or in distant organs. The operating surgeon reported recurrence data based on review of findings on CT, PET, endoscopy, or relevant biopsy analyses whenever possible.

Statistical Analysis

The database was queried to identify relevant clinical and pathological characteristics, which were represented by descriptive statistics (frequency and percentage, median and interquartile range). Cox proportional hazards regression analysis was performed to identify predictors of disease-free survival (DFS) at 5 or more years after esophagectomy. Univariate analyses examined age, sex, performance status,

TABLE 1. Demographic, clinical, and pathological characteristics for patients who were disease-free after 5-years of follow-up (n = 126)

Characteristic	Value
Age at esophagectomy, years, median (IQR), years	63 (55-70)
Male sex, n (%)	97 (77)
Charlson Comorbidity Index = 0, n (%)	65 (52)
Normal activity (performance status = 0), n (%)	81 (64)
Absence of pulmonary comorbidities, n (%)	95 (75)
Tumor location, n (%)	
Upper third	7 (6)
Middle third	22 (17)
Lower third/GEJ	97 (77)
Treatment modality, n (%)	
Neoadjuvant therapy	65 (52)
Surgery ± adjuvant therapy	61 (48)
En bloc resection, n (%)	104 (82)
Two-field	37 (29)
Three-field	67 (53)
Total lymph nodes harvested, n, median (IQR)	30 (21-41)
Histological type, n (%)	
Adenocarcinoma	78 (62)
Squamous cell carcinoma	48 (38)
Histological grade of differentiation, n (%)	
Well differentiated	14 (11)
Moderately differentiated	59 (47)
Poorly differentiated/undifferentiated	53 (42)
Complications, n (%)	55 (44)
Pulmonary	17 (14)
Cardiac	7 (6)
Anastomotic leakage	13 (10)
Recurrent laryngeal nerve injury	3 (2.5)
Chylothorax	3 (2.5)
Wound infection	8 (6)
Other complications	4 (3)

IQR, Interquartile range; GEJ, gastroesophageal junction.

pulmonary comorbidity, neoadjuvant therapy, extent of resection, pathological T classification, pathological N classification, angiolymphatic invasion, histological cell type, and postoperative complications. To avoid overdetermination, the multivariable model included only highly significant ($P < .10$) univariate factors: pulmonary comorbidity, extent of resection, pathological N classification, and angiolymphatic invasion. Collinearity between potential predictors was examined (using the κ statistic) before the final multivariable model was formulated. In the final multivariable model, predictors with a P value $\leq .05$ were deemed significant predictors.

Overall survival (OS) was defined as the time from surgical resection until the date of death or last follow-up. DFS was defined as the time from surgical resection to EC recurrence or death from any cause or last follow-up. Survival probabilities were estimated using Kaplan-Meier survival analysis. Median follow-up time for the cohort was based on surviving patients. All analyses were performed using SPSS version 22.0 (IBM, Armonk, NY).

RESULTS

Clinicopathological Characteristics

Among the 355 patients with LAEC, 126 were disease-free at 5 years, for an actuarial 5-year DFS of

FIGURE 1. OS for the group of patients who were disease-free after 5 years of follow-up (n = 126).

33% (95% confidence interval [CI], 28.1%-37.9%). Patient characteristics are reported in Table 1. The majority were men who had adenocarcinoma of the lower-third of the esophagus and gastroesophageal junction. Clinical staging was accomplished using CT scanning in all 126 patients, along with endoscopic ultrasonography in 70 patients (55.6%) and PET scanning in 80 patients (63.5%). Slightly more than one-half of the patients (51.6 %) received induction therapy (58 patients with chemotherapy only and 7 with chemoradiotherapy). En bloc esophagectomy (2 or 3 fields) was performed in 104 patients (82.5%), and an R-0 resection was accomplished in all patients. Patients treated with an en bloc resection were generally younger ($P = .165$), less likely to have pulmonary comorbidity ($P = .051$), and more likely to have a higher tumor burden (pN1-3: 53% vs 33%; $P = .141$) compared with patients treated with non-en bloc resection (data not shown).

Incidence and Patterns of Recurrence

The 126 patients who are the subject of this report included 10 patients who had developed EC recurrence before the 5-year mark and were treated for recurrence and rendered disease-free. One patient had local recurrence, 6 patients had regional recurrence, and 3 patients had distant recurrence (4 treated by surgery with chemoradiation, 5 treated by definitive chemoradiation, and 1 treated by chemotherapy). Eight patients (6.3%) developed first recurrence more than 5 years after esophagectomy; among those 8 patients, recurrent EC was local only in 1 patient (unresectable and treated by chemotherapy alone), regional only in 1 patient (treated by surgical resection of recurrent laryngeal lymph nodes, followed by chemoradiation), and distant in 6 patients

TABLE 2. Predictors of DFS [recurrence or death (n = 34)] among patients who were disease-free after 5 years of follow-up (n = 126), Cox proportional hazards model

Independent variable	Events, n/N (%)	Univariate predictors		Multivariable predictors*	
		HR (95% CI)	P value	HR (95% CI)	P value
Age at surgery					
<63 y	15/64 (23)	Reference			
>63 y	19/62 (31)	1.28 (0.64-2.56)	.489		
Sex					
Female	8/29 (28)	Reference			
Male	26/97 (27)	1.12 (0.50-2.49)	.782		
Performance status					
0	18/81 (22)	Reference			
≥1	16/45 (36)	0.67 (0.31-1.47)	.318		
Pulmonary comorbidity					
Absence	22/95 (23)	Reference			
Presence	12/31 (39)	2.74 (1.32-5.68)	.007	2.19 (0.99-4.83)	.051
Neoadjuvant therapy					
Neoadjuvant	15/65 (23)	Reference			
Surgery alone	19/61 (31)	0.67 (0.32-1.38)	.278		
Extent of resection					
En bloc	27/104 (26)	Reference			
Non-en bloc	7/22 (32)	4.80 (1.72-3.41)	.003	4.36 (1.52-2.50)	.00
Pathological T classification					
Tis, T0, T1	6/42 (14)	Reference			
T2, T3, T4	28/84 (33)	1.97 (0.75-5.16)	.167		
Pathological N classification					
N0	13/68 (19)	Reference			
N1, N2, N3	21/58 (36)	1.93 (0.96-3.90)	.065	1.87 (0.86-4.05)	.111
Angiolymphatic invasion					
Absence	21/86 (24)	Reference			
Presence	13/40 (33)	2.35 (1.14-4.85)	.021	1.53 (0.67-3.48)	.315
Histological cell type					
Squamous cell carcinoma	14/48 (29)	Reference			
Adenocarcinoma	20/78 (26)	0.92 (0.46-1.85)	.818		
Postoperative complications					
Uncomplicated	19/71 (27)	Reference			
Complicated	15/55 (27)	0.89 (0.44-1.79)	.748		

HR, Hazard ratio; CI, confidence interval. *Only variables with P < .10 were included in the multivariable analysis.

(treated by chemotherapy with or without radiation). Overall, 7 of 18 patients survived at least 5 years after treatment of recurrence (2 treated surgically, 3 treated by definitive chemoradiation, and 2 treated by chemotherapy alone).

Survival

Median follow-up for the 126 surviving patients was 106 months (range, 60-270 months) from the date of surgery and 46 months from the onset of the landmark observation period. Thirty-three patients died after 5 years from either recurrent EC or non-EC-related causes. Kaplan-Meier OS was 94% (95% CI, 89.1%-98.1%) at 7 years, 80% (95% CI, 71.0%-88.6%) at

10 years, and 59% (95% CI, 45.6%-71.4%) at 15 years (Figure 1).

Univariate analysis identified the presence of any pulmonary comorbidity, non-en bloc resection, and angiolymphatic invasion as factors predictive of DFS (Table 2). Pulmonary comorbidity was entered into the multivariable model rather than the CCI, because it was collinear with the CCI, which in turn was not significantly associated with mortality in the univariate analyses (data not shown). In the multivariable model, only non-en bloc resection (hazard ratio, 4.36; 95% CI, 1.52-12.50; P = .006) was a significant independent predictor of DFS after the 5-year time point. The results of the multivariable model were unchanged after excluding 13 patients with pT1N0 treated by esophagectomy alone (data not shown).

TABLE 3. Types of second primary cancers (n = 23)

Second primary cancer	n (%)
Prostate cancer	6 (4.8)
Lung cancer	3 (2.4)
Gastric cancer	2 (1.6)
Head and neck cancers	2 (1.6)
Breast cancer	2 (1.6)
Ovarian carcinoma	2 (1.6)
Skin cancers (melanoma and SCC)	2 (1.6)
Urinary bladder cancer	2 (1.6)
Colon cancer	1 (0.8)
Meningioma	1 (0.8)

SCC, Squamous cell carcinoma.

Other Primary Cancers

Twenty-three patients developed a second primary cancer, including 13 who developed second primary cancer after 5-years of follow-up. The types of second primary cancers are listed in Table 3. Prostate cancer was the most frequent type, occurring in 6 patients, followed by lung cancer, occurring in 3 patients.

Causes of Death

There were a total of 33 deaths among the 126 patients, for a 10-year Kaplan-Meier projected mortality rate of 20% (95% CI, 11.2%-28.8%). Seven deaths were due to recurrent EC, 4 were from a second primary cancer (gastric, ovarian, urinary bladder, and skin), and 22 were from a non-cancer-related cause. Pulmonary disease was the most common cause of non-cancer-related death (10 of 33 deaths), followed by cardiovascular disease. The causes of deaths are listed in Table 4.

DISCUSSION

The majority of previous studies investigating the long-term outcomes after esophagectomy for EC focused on patients' quality of life, alimentary satisfaction, and gastrointestinal symptoms.^{6,7} Few if any studies have evaluated oncologic outcomes in patients surviving at least 5 years after esophagectomy for cancer. In this

sense, it is difficult to know whether these patients can be considered "cured" of their disease.^{8,9} Here we report data on survival and recurrence in patients with LAEC surviving at least 5 years after resection, as well as other causes of death in this highly selected patient population. Because we assumed that patients with early-stage disease are highly likely to be cured of EC,¹⁰ we focused on patients with locally advanced disease treated with either esophagectomy alone or preoperative therapy followed by resection.

Our data permit several important observations. The 33% actuarial 5-year DFS of this cohort of patients with LAEC is promising. These excellent results are likely the result of accurate preoperative staging, standardization of surgical and perioperative management, and the use of multimodality treatment strategies. We did not investigate the relative contribution of each of these variables in improving survival, but rather focused on what occurs at and beyond the 5-year mark.

Despite being free of disease at 5 years, patients with LAEC may remain at risk for disease recurrence. In addition, patients who are disease-free after treatment of initial recurrence before 5 years continue to be at risk for further disease progression. These data suggest that, given the risk of recurrence, continued surveillance of patients with EC may be necessary perhaps as long as 10 years after resection. Importantly, surveillance does not appear to be futile, given that 7 of 18 patients treated for recurrent EC survived at least 5 years after this treatment. Our results do not permit us to advocate for a specific treatment strategy once recurrence occurs, but aggressive local therapy with curative intent should be pursued whenever possible.¹¹

In the present study, we identified en bloc resection as the sole independent predictor of DFS in our patients who had reached the 5-year time point. It is perhaps surprising that a surgical technique should remain predictive of survival after 5 years. It is possible that patients undergoing en bloc resection were selected for that surgical procedure because of better performance status, fewer comorbidities, or less frail appearance. Such a group might be expected to have a longer OS on the basis of those differences alone. Nonetheless, we also believe that improved local control translates into less disease recurrence and improved survival. In a previous report, we identified en bloc resection as an independent predictor of freedom from recurrence in a larger cohort of 465 patients.² The small number of patients in the present study who experienced recurrence after 5 years make it difficult to draw statistically meaningful conclusions in this cohort. A recent study suggested that T classification and age may be important predictors of survival after the 5-year time point¹⁰; however, with a similar number

TABLE 4. Causes of death (n = 33)

Cause	n (%)
Recurrence of esophageal cancer	7 (21.2)
Pulmonary diseases	10 (30.3)
Cardiac diseases	6 (18.2)
Second primary cancer	4 (12.1)
Stroke	2 (6.1)
Renal failure	1 (3)
Unknown cause	3 (9.1)

of patients, we did not find those 2 factors to be significant.

Second primary cancers developed in 23 patients who were disease-free at the onset of the observation period. This suggests continued the need for careful follow-up of these long-term survivors.

Finally, chronic pulmonary disease was responsible for nearly one-third of all deaths in our cohort. Multiple quality of life studies have identified reflux-related chronic nocturnal cough and possible aspiration as significant long-term consequences of esophagectomy. Greene and colleagues¹² reported that chronic respiratory symptoms such as cough were present in >25% of their patients and that aspiration requiring hospitalization occurred in 15%. Similarly, Derogar and Lagergren¹³ reported a prospective nationwide quality of life study among Swedish patients surviving 5 years after esophagectomy. Trouble with cough persisted in as many as 50% of patients at 5 years. These potentially modifiable adverse events of esophagectomy may be mitigated by proper counseling of patients to avoid meals for 2 to 3 hours before bedtime and to sleep with the head of the bed elevated. Certainly recurrent microaspiration occurs in some patients and can lead to chronic pulmonary damage. Regardless of the oncologic issues, postesophagectomy patients need to be followed by physicians familiar with the long-term sequelae of esophagectomy and their management.

Although the present study is limited by its retrospective design, the data were prospectively collected in our database by a dedicated data manager and updated at regular intervals. The patients evaluated were operated on over a 20-year period. It is possible that changes in treatment modalities could have had variable effects on patient outcomes; however, these factors are accounted for in the multivariable analysis. Another limitation is the lack of a consistent method of preoperative staging, with 55% to 63% of patients staged by endoscopic ultrasonography and PET scanning. Despite this limitation, only 13 patients (10%) were eventually found to have pT1N0 disease, and the results remained the same after those patients were excluded from the analysis.

We conclude that despite being alive and disease-free at 5 years after esophagectomy for LAEC, a subset of patients remains at risk for recurrence of EC, for another primary cancer, and for pulmonary disease possibly related to the sequelae of esophagectomy. These results suggest the need for continued careful follow-up of these patients.

Conflict of Interest Statement

Authors have nothing to disclose with regard to commercial support.

You can watch a Webcast of this AATS meeting presentation by going to: http://webcast.aats.org/2015/Video/Wednesday/04-29-15_608_0908_Ghaly.mp4.

References

1. Stein HJ, von Rahden BH, Siewert JR. Survival after oesophagectomy for cancer of the oesophagus. *Langenbecks Arch Surg*. 2005;390:280-5.
2. Lee PC, Mirza FM, Port JL, Stiles BM, Paul S, Christos P, et al. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. *J Thorac Cardiovasc Surg*. 2011;141:1196-206.
3. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982;5:649-55.
4. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? *Ann Surg*. 2001;234:581-7.
5. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. *AJCC Cancer Staging Manual*. 7th ed. New York: Springer; 2010.
6. McLarty AJ, Deschamps C, Trastek VF, Allen MS, Pairalero PC, Harmsen WS. Esophageal resection for cancer of the esophagus: long-term function and quality of life. *Ann Thorac Surg*. 1997;63:1568-72.
7. Jacobs M, Macefield RC, Elbers RG, Simikova K, Korfage IJ, Smets EM, et al. Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. *Qual Life Res*. 2014;23:1097-115.
8. Fahn HJ, Wang LS, Huang BS, Huang MH, Chien KY. Tumor recurrence in long-term survivors after treatment of carcinoma of the esophagus. *Ann Thorac Surg*. 1994;57:677-81.
9. Kakuta T, Kosugi S, Kanda T, Ishikawa T, Hanyu T, Suzuki T, et al. Prognostic factors and causes of death in patients cured of esophageal cancer. *Ann Surg Oncol*. 2014;21:1749-55.
10. Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A. Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy. *Ann Surg Oncol*. 2011;18:1766-74.
11. Port JL, Nasar A, Lee PC, Paul S, Stiles BM, Andrews W, et al. Definitive therapy for isolated esophageal metastases prolongs survival. *Ann Thorac Surg*. 2012;94:413-9.
12. Greene CL, DeMeester SR, Worrell SG, Oh DS, Hagen JA, DeMeester TR. Alimentary satisfaction, gastrointestinal symptoms, and quality of life 10 or more years after esophagectomy with gastric pull-up. *J Thorac Cardiovasc Surg*. 2014;147:909-14.
13. Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. *J Clin Oncol*. 2012;30:413-8.

Key Words: esophageal cancer, disease-free survival, en bloc resection, recurrence

Discussion

Dr S. DeMeester (Los Angeles, Calif). I would like to congratulate the authors on an important and nicely presented study. I found 3 important findings and want to highlight those. 96% of recurrences occurred within the first 5 years, but late recurrence beyond 5 years did occur. Secondly, recurrence of esophageal cancer is not uniformly fatal, since the 10-year overall survival of patients with recurrence was 31%. Thus, follow-up and treatment of recurrence is appropriate in patients with esophageal cancer. Thirdly, surviving esophageal cancer does not ensure you won't die from cancer, since second primary malignancies occurred in about 9% of patients and led to

death in about a quarter of those patients. My questions will focus on those three areas.

We found that late recurrence was more likely in those with early-stage disease. Why did you exclude patients with early-stage disease who had an esophagectomy, and perhaps would you have seen more late recurrences had they been included?

Dr Stiles. I think that is a very fair point. For this paper, though, we really wanted to move the discussion away from early-stage patients. I think it is acknowledged by most referring doctors, oncologists, primary care doctors, and the public that we can all cure early-stage, stage I, esophageal cancer. We still see a bit of a therapeutic nihilism, though, with locally-advanced disease. We really wanted to just focus on those patients and make the point that some of these patients are cured for the long term as well.

Dr DeMeester. Secondly, what was the longest interval from surgery to first recurrence in your series, and did it differ in patients who had neoadjuvant therapy versus primary surgical resection?

Dr Stiles. It's incredible. One patient recurred at 10 years with a liver metastasis. Almost all of the recurrences after 5 years were actually distant, as I showed you. There was no difference for the group of 32 patients at 5 years in recurrence by neoadjuvant therapy versus surgery alone. The neoadjuvant therapy patients tended to recur a little bit earlier than the surgery patients, but not statistically different. It's interesting that the reverse was true in the whole cohort, where neoadjuvant therapy seemed to protect them

from recurrence a little bit, although, again, not statistically significant.

Dr DeMeester. Third, how was recurrence detected? What would be your recommendations for post-resection follow-up in terms of the intervals and types of scans or testing, including upper endoscopy?

Dr Stiles. We were limited in that we didn't go back and look at how recurrence was detected. I would certainly refer people to your paper on recurrence, which I think is excellent. In that, I think you said that 60% of your cases were detected by CT. I suspect that most of our recurrences were by CT and very few were by symptoms, similar to your study. We tend to get a CT yearly, and I would anticipate that that is how most were detected.

Dr DeMeester. Lastly, did patients who had neoadjuvant therapy have a similar frequency of second primary cancers as those treated with surgery alone? Along those lines, were there any long-term effects of the neoadjuvant therapy in those patients who survived long term?

Thank you.

Dr Stiles. Thank you, Dr DeMeester. That, too, is a great point. In our series, we didn't see any difference. We may have expected it, but the rates of second primary malignancies were almost identical. Certainly there are lots of data in other malignancies, that there is a long-term risk of second cancers from radiation in particular, but also from the chemotherapy. In ours we didn't see that. I don't actually recall looking at pulmonary complications in neoadjuvant therapy, but I think that is another thing to think about.